28
Participants
Start Date
October 19, 2021
Primary Completion Date
July 31, 2027
Study Completion Date
April 30, 2032
Active Stimulation
Stimulation will be turned ON and applied during each day of the period.
Sham Stimulation
Sham stimulation will be provided during the period
Baricitinib
Baricitinib (2 mg) is administered daily during the period.
Background Treatment
Stable dose of standard background treatment (e.g., csDMARD therapy)
RECRUITING
NYU Langone, Brooklyn
RECRUITING
Altoona Center for Clinical Research, Altoona
RECRUITING
The Osteoporosis & Clinical Trials Center, Hagerstown
WITHDRAWN
Pinnacle Research Group, LLC, Anniston
RECRUITING
Arthritis & Rheumatology Institute, Allen
RECRUITING
Southwest Rheumatology Research, Mesquite
WITHDRAWN
Metroplex Clinical Research Center, Dallas
RECRUITING
St. David's Healthcare, Austin
RECRUITING
Tekton Research, Austin
RECRUITING
Medvin Research - Whittier, Whittier
RECRUITING
Medvin Research - Covina, Covina
RECRUITING
Oregon Health & Science University, Portland
RECRUITING
Academic Medical Center (AMC) Dept of Rheumatology & Clinical Immunology, Amsterdam
RECRUITING
Maxima Medical Center, MMC, Eindhoven
Lead Sponsor
Collaborators (2)
NAMSA
OTHER
Q2 Solutions
INDUSTRY
Galvani Bioelectronics
INDUSTRY